PHAT
Phathom Pharmaceuticals, Inc.
Key Financials
Revenue
$175.1M
↑ 216.9%
Net Income
$-221247000
↑ 33.8%
Total Assets
$259.1M
↓ 31.5%
EPS (Diluted)
$-3.03
↑ 42.7%
Gross Profit
$152.5M
↑ 222.6%
Operating Income
$-159986000
↑ 42.3%
Cash & Equivalents
$130.0M
↓ 56.3%
Total Liabilities
$697.3M
↑ 10.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 6/23/2026 | View on SEC |
| 4 | 5/27/2026 | View on SEC |
| 4 | 5/21/2026 | View on SEC |
| 4 | 5/21/2026 | View on SEC |
| 4 | 5/21/2026 | View on SEC |
| 4 | 5/21/2026 | View on SEC |
| 4 | 5/21/2026 | View on SEC |
| 4 | 5/21/2026 | View on SEC |
| 4 | 5/21/2026 | View on SEC |
| 8-K | 5/21/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | PHAT |
| Company Name | Phathom Pharmaceuticals, Inc. |
| CIK | 1783183 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (877) 742-8466 |